Tag: Quality of life

Posted on

Quality of life in obstructive hydrocephalus: endoscopic third ventriculostomy compared to cerebrospinal fluid shunt

Childs Nerv Syst (2010) 26:75–79.DOI 10.1007/s00381-009-0983-7

In the current literature, there are essentially no comparisons of quality of life (QOL) outcome after endoscopic third ventriculostomy (ETV) and shunt in childhood hydrocephalus. Our objective was to compare QOL in children with obstructive hydrocephalus, treated with either ETVor shunt. Methods A cross-sectional survey was conducted at SickKids, Toronto of children between ages five and 18 years, with obstructive hydrocephalus due to aqueductal obstruction and no other brain abnormalities. Measures of QOL were the Hydrocephalus Outcome Questionnaire and the Health Utilities Index Mark 3. A subset of patients was given the Wechsler Intelligence Scales for Children (WISC-IV). Results A total of 47 of 59 (80%) eligible patients participated (24 had ETV as primary treatment, 23 had shunt as primary treatment), with a mean age of 12.1 years (standard deviation 3.9) at assessment. The ETV group was older at initial surgery (p<0.001) and had larger ventricle size at last follow-up (p= 0.047). In all QOL measures, there were no significant differences between the ETV group and shunt group (all p≥ 0.09). Treatment failure, hydrocephalus complications, and the presence of a functioning ETV at assessment were not associated with QOL differences. Among the 11 children (six ETV, five shunt) who were given the WISC-IV, there were no significant differences between the scores of the ETV group and shunt group (all p≥0.11). Conclusions This is the first study to provide a meaningful comparison of QOL after ETV and shunt in children. These preliminary results suggest that there is no obvious difference in QOL after ETVand shunt.

Posted on

Understanding inconsistencies in patient-reported outcomes after spine treatment: response shift phenomena

Not uncommonly, spine surgeons and physiatrists note a mismatch between patient-reported outcome measures, where one measure might indicate a good outcome and another indicates an inferior outcome after spine treatment. This may be the result of patient characteristics that lead to changes in internal standards, values, and conceptualization of their own health-related quality of life. This can result in a ‘‘moving goal post’’ when a self-report outcome measure is used for prepost comparisons. These ‘‘response shifts’’ may obfuscate relevant changes of interest to clinicians and are meaningful and worthy of study in and of themselves.

PURPOSE: To provide a background on response shift with an emphasis on distinctions relevant to spinal interventions, both surgical and nonsurgical. To describe current methods for detecting and investigating response shift phenomena, and to propose specific hypotheses that can be tested in collaborative research. METHODS AND RESULTS: Two types of methods will be briefly described: methods that require new data collection; and methods that use recent statistical and technical advances to implement secondary analysis of existing data. Two specific testable hypotheses for spinal disorders are suggested along with suggested methods for testing these hypotheses. CONCLUSIONS: A response shift will cause the patient to use the same functional outcome report measure differently pre- and posttreatment. Response shift phenomena are likely to affect the measurement properties of standard spine outcome measures and to obfuscate differences between treatments in clinical trials and cost-effectiveness studies. They point to a need for developing strategies in clinical practice to manage response shifts so that they enhance patient well-being.

Posted on

Vestibular Schwannoma: Surgery or Gamma-Knife radiosurgery?. A prospective, non-randomized study

Neurosurgery 64:654–663, 2009 DOI: 10.1227/01.NEU.0000340684.60443.55

OBJECTIVE: To conduct a prospective, open, nonrandomized study of treatment- associated morbidity in patients undergoing microsurgery or gamma knife radiosurgery (GKRS) for vestibular schwannomas.

METHODS: Ninety- one patients with vestibular schwannomas with a maximum tumor diameter of 25 mm in the cerebellopontine angle were treated according to a prospective protocol either by GKRS (63 patients) or open microsurgery (28 patients) using the suboccipital approach. Primary end points included hearing function, according to the Gardner- Robertson scale, and facial nerve function, according to the House- Brackmann scale at 2 years. Clinical data included a balance platform test, score for tinnitus and vertigo using a visual analog scale, and working ability. Patients responded to the qualityof- life questionnaires Short- Form 36 and Glasgow Benefit Inventory.

RESULTS: Three elderly GKRS patients withdrew; all remaining patients were followed for 2 years. Both primary end points were highly significant in favor of GKRS (P<0.001). Evidence of reduced facial nerve function (House- Brackmann grade 2 or poorer) at 2 years was found in 13 of 28 open microsurgery patients and 1 of 60 GKRS patients. Thirteen of 28 patients who underwent surgery had serviceable hearing (Gardner- Robertson grade A or B) preoperatively, but none had serviceable hearing postoperatively. Twentyfive of 60 GKRS patients had serviceable hearing before treatment, and 17 (68%) of them had serviceable hearing 2 years after treatment. The tinnitus and vertigo visual analog scale score, as well as balance platform tests, did not change significantly after treatment, and working status did not differ between the groups at 2 years. Quality of life was significantly better in the GKRS group at 2 years, based on the Glasgow Benefit Inventory questionnaire. One GKRS patient required operative treatment within the 2-year study period.

CONCLUSION: This is the second prospective study to demonstrate better facial nerve and hearing outcomes from GKRS than from open surgery for small- and medium- sized vestibular schwannomas.

Posted on

Neurological outcome of long-term glioblastoma survivors

J Neurooncol (2009) 95:301–305 DOI 10.1007/s11060-009-9946-9

Extended survival of 3 or more years is rare in patients with glioblastoma (GBM) but is becoming more common. Clinical outcome has not been well studied. We reviewed GBM patients at Memorial Sloan-Kettering Cancer Center between 2001 and 2003 who were seen for two or more visits. Patient characteristics and long-term clinical outcomes were reviewed for patients who had survived 3 or more years following diagnosis. Thirty-nine (11%) of 352 GBM patients were identified as long-term survivors. Median survival was 9.15 years (range: 3–18 years). Median age was 47 years (range: 16–69); 13% were 65 years or older. Median KPS was 90 (range: 50–100). One long-term survivor underwent biopsy alone; 19 patients each had either complete or subtotal resection. All received focal radiotherapy (RT) with a median dose of 5940 cGy; 18% received concurrent temozolomide. Adjuvant chemotherapy was administered to 35 (90%). Twelve patients (31%) remained in continuous remission. Twenty-seven had tumor progression a median of 29.2 months after diagnosis (range: 1.2–167 months); 18 had multiple relapses. Median KPS at last follow-up was 70 (range: 40–100); 85% of long-term survivors had at least one significant neurologic deficit. Eleven (28%) had clinically significant RT-induced leukoencephalopathy, 9 (23%) developed RT necrosis and 9 (23%) treatment-related strokes. Treatment-related complications occurred a median of 2.7 years from diagnosis (range: 0.9–11.5 years).

Long-term survivors remain rare, but are found across all age groups despite multiple recurrences; clinically significant delayed complications of treatment are common.

Proudly powered by WordPress